AR056198A1 - Un proceso para la fabricacion de una composicion farmaceutica tipo tableta - Google Patents

Un proceso para la fabricacion de una composicion farmaceutica tipo tableta

Info

Publication number
AR056198A1
AR056198A1 ARP060104126A ARP060104126A AR056198A1 AR 056198 A1 AR056198 A1 AR 056198A1 AR P060104126 A ARP060104126 A AR P060104126A AR P060104126 A ARP060104126 A AR P060104126A AR 056198 A1 AR056198 A1 AR 056198A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
hydrogen
group
sulfur
halogen
Prior art date
Application number
ARP060104126A
Other languages
English (en)
Inventor
Susanne Page
Hashim A Ahmed
Navnit Hargovindas Shah
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37671050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056198(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR056198A1 publication Critical patent/AR056198A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicacion 1: Un proceso para la fabricacion de una composicion farmacéutica de tipo tableta, en el que el ingrediente farmacéutico activo es de la formula (1), en la que R es alquilo inferior, alcoxi inferior, halogeno o trifluorometilo; R1 es halogeno o hidrogeno; y cuando p es 1, R1 además de los substituyentes anteriores, puede combinarse con R para formar un resto -CH=CH-CH=CH-; R2 y R2' con independencia entre sí son hidrogeno, halogeno, trifluorometilo, alcoxi inferior o ciano; y cuando n es 1, R2 y R2' además de los substituyentes anteriores, puede formar un resto -CH=CH-CH=CH-, sin substituir o substituido por uno o dos substituyentes elegidos entre alquilo inferior o alcoxi inferior; R3 y R3' son hidrogeno, alquilo inferior o junto con el átomo de carbono al que están unidos, forman un grupo cicloalquilo; R4 es hidrogeno, -N(R5)(CH2)nOH, -N(R5)S(O)2-alquilo inferior, -N(R5)S(O)2-fenilo, -N=CH-N(R5)2, -N(R5)C(O)R5, o los radicales de formulas (2) y (3); R5 es hidrogeno, cicloalquilo C3-6, bencilo, o alquilo inferior; R6 es hidrogeno, hidroxi, alquilo inferior, -(CH2)nCOO-(R5), -N(R5)CO-alquilo inferior, hidroxi-alquilo inferior, -(CH2)nCN, -(CH2)nO(CH2)nOH, -CHO o un anillo heterocíclico de 5 o 6 eslabones que contiene de 1 a 4 heteroátomos elegidos entre el grupo formado por oxígeno, nitrogeno, y azufre, y uno de los átomos de carbono de dicho anillo está sin substituir o substituido por un grupo oxo, dicho anillo heterocíclico está unido directamente al resto de la molécula o está unido mediante un grupo alquileno; el radical (2) es una amina terciaria cíclica que puede tener un heteroátomo adicional elegido entre el grupo formado por oxígeno, nitrogeno, o azufre, en la que cualquier azufre que esté presente en el anillo es tio o puede oxidarse a sulfoxido o dioxido de azufre, a través del cual dicha amina terciaria cíclica se une directamente al resto de la molécula o bien se une mediante un grupo de engarce del tipo - (CH2)nN(R5)-; X es -C(O)N(R5)-, -(CH2)mO-, -(CH2)mN(R5)-, -N(R5)C(O)-, o -N(R5)(CH2)m-; n, p, y q con independencia entre sí son un numero de 1 a 4; y m es el numero1 o 2; y las sales de adicion de ácido farmacéuticamente aceptables del mismo y un poloxámero soluble en agua se procesan simultáneamente por extrusion de masa fundida caliente, antes de mezclarse con los demás ingredientes, y en el que la composicion de la tableta puede revestirse posteriormente con una composicion que consta de un sistema de recubrimiento de tipo película de liberacion inmediata y agua purificada.
ARP060104126A 2005-09-23 2006-09-21 Un proceso para la fabricacion de una composicion farmaceutica tipo tableta AR056198A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71979305P 2005-09-23 2005-09-23

Publications (1)

Publication Number Publication Date
AR056198A1 true AR056198A1 (es) 2007-09-26

Family

ID=37671050

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104126A AR056198A1 (es) 2005-09-23 2006-09-21 Un proceso para la fabricacion de una composicion farmaceutica tipo tableta

Country Status (26)

Country Link
US (3) US20070071813A1 (es)
EP (1) EP1928427B1 (es)
JP (2) JP5523706B2 (es)
KR (1) KR20080043852A (es)
CN (2) CN101267808A (es)
AR (1) AR056198A1 (es)
AT (1) ATE453384T1 (es)
AU (1) AU2006298898B2 (es)
BR (1) BRPI0616108A2 (es)
CA (1) CA2623237C (es)
DE (1) DE602006011485D1 (es)
DK (1) DK1928427T3 (es)
ES (1) ES2335922T3 (es)
HK (1) HK1198914A1 (es)
HR (1) HRP20100111T1 (es)
IL (1) IL189929A (es)
MY (1) MY143784A (es)
NO (1) NO340473B1 (es)
NZ (1) NZ566419A (es)
PL (1) PL1928427T3 (es)
PT (1) PT1928427E (es)
RU (1) RU2431473C2 (es)
SI (1) SI1928427T1 (es)
TW (1) TWI375572B (es)
WO (1) WO2007039420A1 (es)
ZA (1) ZA200802272B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150041174A (ko) 2005-11-08 2015-04-15 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ 결합 카세트 수송체의 헤테로사이클릭 조정제
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
AU2008251504B2 (en) 2007-05-09 2013-07-18 Vertex Pharmaceuticals Incorporated Modulators of CFTR
DE102007027067A1 (de) * 2007-06-12 2008-12-18 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Vardenafil Hydrochlorid Trihydrat
EP3170818B1 (en) 2007-12-07 2020-02-19 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
DK2639224T3 (en) 2007-12-07 2016-10-17 Vertex Pharma A process for the preparation of cycloalkylcarboxiamido-pyridinbenzoesyrer
MX2010007645A (es) * 2008-01-11 2010-11-05 Cipla Ltd Forma de dosis farmaceutica solida.
WO2009108657A2 (en) 2008-02-28 2009-09-03 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
HUE056525T2 (hu) 2010-04-07 2022-02-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
JP5917964B2 (ja) * 2012-03-19 2016-05-18 富士ゼロックス株式会社 錠剤、錠剤の製造方法、錠剤管理装置、錠剤照合装置及びプログラム
WO2015068744A1 (ja) 2013-11-08 2015-05-14 キッセイ薬品工業株式会社 カルボキシメチルピペリジン誘導体
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
WO2016038356A1 (en) * 2014-09-08 2016-03-17 University Of Central Lancashire Solid dosage form production
DK3221692T3 (da) 2014-11-18 2021-08-23 Vertex Pharma Fremgangsmåde til udførsel af tests med høj kapacitet ved hjælp af højtryksvæskekromatografi
CN104586770A (zh) * 2014-12-30 2015-05-06 山东博迈康药物研究有限公司 一种盐酸帕唑帕尼的热熔挤出制剂及其制备方法
TWI815829B (zh) 2017-11-14 2023-09-21 美商默沙東有限責任公司 作為吲哚胺2,3-二氧酶(ido)抑制劑之新穎經取代二芳基化合物
CN108159008B (zh) * 2018-02-27 2021-03-23 河北化工医药职业技术学院 缬沙坦咀嚼片的制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1557420A (en) 1977-03-10 1979-12-12 Soc D Etudes Prod Chimique Preparation of isobutyramide derivatives
EP0089153B1 (en) 1982-03-17 1986-09-24 Smith Kline & French Laboratories Limited Pyridine derivatives
JPS60184008A (ja) * 1984-03-02 1985-09-19 Eisai Co Ltd テオフイリンまたはアミノフイリン含有組成物
US4745123A (en) 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
GB8607312D0 (en) 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
GB8607313D0 (en) 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
CA1339423C (en) 1988-09-14 1997-09-02 Yuji Ono Pyridine compounds and pharmaceutical use thereof
US4994456A (en) 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
US4973597A (en) 1989-06-30 1990-11-27 Eli Lilly And Company Anticonvulsant agents
HU207047B (en) 1989-11-07 1993-03-01 Richter Gedeon Vegyeszet Process for producing new pyridine derivatives and pharmaceutical copositions comprising same
US5364943A (en) 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
GB9021056D0 (en) 1990-09-27 1990-11-07 Pfizer Ltd Antiarrhythmic agents
GB9214120D0 (en) 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
WO1994003429A1 (en) * 1992-07-31 1994-02-17 Merck Sharp & Dohme Limited Substituted amines as tachykinin receptor antagonists
US5387595A (en) * 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
GB9305672D0 (en) 1993-03-19 1993-05-05 Wyeth John & Brother Ltd Amide derivatives
WO1994027604A1 (fr) 1993-05-28 1994-12-08 Taisho Pharmaceutical Co., Ltd. Utilisation medicale d'un derive de pyridine
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
NZ264063A (en) 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
ES2164758T3 (es) * 1993-12-29 2002-03-01 Merck Sharp & Dohme Derivados de morfolina sustituidos y su uso como agentes terapeuticos.
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
NZ287284A (en) 1994-06-06 1998-10-28 Warner Lambert Co N-[2-(phenyl(substituted)ethylamino)-1-(indolylmethyl)-1-methyl -2-oxoethyl] carbamic acid ester derivatives, medicaments and intermediates
AU2753195A (en) 1994-06-24 1996-01-19 Taisho Pharmaceutical Co., Ltd. Pyridine derivative
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6294537B1 (en) * 1995-03-17 2001-09-25 Sanofi-Synthelabo Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
TW394773B (en) 1995-03-24 2000-06-21 Takeda Chemical Industries Ltd Cyclic compounds for antagonizing tachykinin receptor, substance p receptor and neurokinin a receptor, their production and pharmaceutical composition
ES2214604T3 (es) 1996-03-29 2004-09-16 Pfizer Inc. Derivados de la 6-fenilpiridil-2-amina.
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
AU4885097A (en) 1996-11-08 1998-06-03 Sankyo Company Limited Arylureas or arylmethylcarbamoyl derivatives
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
JPH11189546A (ja) 1997-12-25 1999-07-13 Saitama Daiichi Seiyaku Kk 経皮吸収促進剤
JPH11189548A (ja) * 1997-12-25 1999-07-13 Toshio Sato 無晶性医薬組成物及びその製造方法
DK1394150T3 (da) * 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
BR0008489A (pt) 1999-02-24 2002-02-05 Hoffmann La Roche Derivados de fenil- e piridinila
ES2208205T3 (es) 1999-11-29 2004-06-16 F. Hoffmann-La Roche Ag 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-otolil-piridin-3-il)-isobutiramida.
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
MXPA03009971A (es) * 2001-05-03 2004-02-12 Hoffmann La Roche FORMA DE DOSIFICACIoN FARMACEUTICA DE MESILATO DE NELFINAVIR AMORFO.
KR100810320B1 (ko) 2005-06-16 2008-03-04 삼성전자주식회사 디지털 방송 재생기가 방송 중에 제공되는 전화번호를이용하여 발신하는 방법 및 그 디지털 방송 시스템

Also Published As

Publication number Publication date
HRP20100111T1 (hr) 2010-04-30
AU2006298898B2 (en) 2011-06-30
JP2013049686A (ja) 2013-03-14
KR20080043852A (ko) 2008-05-19
RU2431473C2 (ru) 2011-10-20
TW200803922A (en) 2008-01-16
CA2623237A1 (en) 2007-04-12
IL189929A0 (en) 2008-08-07
SI1928427T1 (sl) 2010-03-31
US8852634B2 (en) 2014-10-07
MY143784A (en) 2011-07-15
NO340473B1 (no) 2017-04-24
EP1928427B1 (en) 2009-12-30
DK1928427T3 (da) 2010-03-08
ES2335922T3 (es) 2010-04-06
CA2623237C (en) 2013-07-09
TWI375572B (en) 2012-11-01
ATE453384T1 (de) 2010-01-15
AU2006298898A1 (en) 2007-04-12
PL1928427T3 (pl) 2010-06-30
US20070071813A1 (en) 2007-03-29
WO2007039420A1 (en) 2007-04-12
DE602006011485D1 (de) 2010-02-11
RU2008109823A (ru) 2009-10-27
NZ566419A (en) 2010-03-26
PT1928427E (pt) 2010-03-01
BRPI0616108A2 (pt) 2011-06-07
NO20081325L (no) 2008-06-18
EP1928427A1 (en) 2008-06-11
HK1198914A1 (en) 2015-06-19
US20130189362A1 (en) 2013-07-25
JP2009508907A (ja) 2009-03-05
CN103893145A (zh) 2014-07-02
IL189929A (en) 2012-12-31
CN101267808A (zh) 2008-09-17
US20110070303A1 (en) 2011-03-24
ZA200802272B (en) 2009-01-28
JP5523706B2 (ja) 2014-06-18

Similar Documents

Publication Publication Date Title
AR056198A1 (es) Un proceso para la fabricacion de una composicion farmaceutica tipo tableta
AR039203A1 (es) Derivados de quinazolina
AR062110A1 (es) Derivado de anillo fusionado de espiroquetas y su uso como farmaco antidiabetico
AR050952A1 (es) Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1.
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
AR049464A1 (es) Antagonistas de receptores de acetilcolina muscarinicos. composiciones farmaceuticas
DE60322359D1 (de) Imidazopyridinderivate als kinaseinhibitoren
AR057894A1 (es) Derivados de tiofeno
HRP20140151T1 (hr) Derivati spiro-indola za lijeäśenje parazitnih bolesti
AR053195A1 (es) Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo
AR055669A1 (es) Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
AR060658A1 (es) Derivados de diceto-piperazina y piperidina como agentes antivirales
AR047056A1 (es) Derivados de pirimidinas condensadas. composiciones farmacéuticas
AR069772A1 (es) Derivados heterociclicos, una composicion farmaceutica y un juego que los comprenden y su uso en la preparacion de un medicamento para el tratamiento de una infeccion parasitaria.
MX2009007954A (es) Derivado de heterocicliden-n-(aril) acetamida.
AR043658A1 (es) Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona
HRP20090264T1 (en) Phenyl-piperazin methanone derivatives
AR054231A1 (es) Composiciones farmaceuticas
AR045959A1 (es) Derivados de pirazolo- e imidazo-pirimidina
EP3986470A2 (en) Small molecule target bromo/acetyl proteins and uses thereof
CA3109617A1 (en) Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use
AR040126A1 (es) Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento
AR077301A1 (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano como antagonistas de 5-ht1a y 5-ht1b
AR023292A1 (es) Un compuesto derivado de imidazol, un procedimiento para su preparacion, y un medicamento y una composicion farmaceutica que comprende a dicho compuesto

Legal Events

Date Code Title Description
FC Refusal